AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 billion deal

(Reuters) – AstraZeneca said on Monday it will acquire U.S.-based clinical-stage biopharmaceutical company CinCor Pharma Inc in a deal valued at about $1.8 billion.

(Reporting by Radhika Anilkumar in Bengaluru; Editing by Savio D’Souza)